0XOD.LSE UroGen Pharma Ltd.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 0XOD.LSE undervalued?

Graham number

The Graham number of UroGen Pharma Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

UroGen Pharma Ltd. fundamental analysis

No fundamental analysis for UroGen Pharma Ltd. yet.

UroGen Pharma Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment …

Full company profile